Microscopic Colitis and Risk of Incident Psoriasis: A Nationwide Population-Based Matched Cohort Study
David Bergman,Bjorn Roelstraete,Jiangwei Sun,Fahim Ebrahimi,Rickard Lidström,Axel Svedbom,Mona Ståhle,Jonas F Ludvigsson
DOI: https://doi.org/10.2147/clep.s454677
2024-03-30
Clinical Epidemiology
Abstract:David Bergman, 1 Bjorn Roelstraete, 1 Jiangwei Sun, 1 Fahim Ebrahimi, 1, 2 Rickard Lidström, 3 Axel Svedbom, 4, 5 Mona Ståhle, 4 Jonas F Ludvigsson 1, 6, 7 1 Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden; 2 Department of Gastroenterology and Hepatology, Clarunis University Center for Gastrointestinal and Liver Diseases, Basel, Switzerland; 3 Diagnostiskt Centrum Hud, Stockholm, Sweden; 4 Division of Dermatology and Venereology, Department of Medicine, Karolinska Institutet, Stockholm, Sweden; 5 Dermatology and Venereology Clinic, Karolinska University Hospital, Stockholm, Sweden; 6 Department of Pediatrics, Orebro University Hospital, Orebro, Sweden; 7 Department of Medicine, Columbia University College of Physicians and Surgeons, New York, NY, USA Correspondence: David Bergman, Email Background: Microscopic colitis (MC) has been associated with several immune-mediated diseases including psoriasis, but earlier research has been limited to psoriasis occurring before MC. Data from large-scale cohort studies investigating MC and risk of future psoriasis are lacking. Objective: To examine the association between MC and psoriasis. Methods: In a nationwide, population-based, matched cohort study in Sweden from 2007 to 2021, we identified 8404 patients with biopsy-verified MC (diagnosed in 2007– 2017), 37,033 matched reference individuals, and 8381 siblings without MC. Information on MC was obtained through the ESPRESSO cohort (a Swedish histopathology database with nationwide coverage). Using Cox regression, we calculated hazard ratios (HRs) and 95% confidence intervals (CIs) for psoriasis up until 2021. Results: During a median follow-up of 9.2 years (interquartile range = 6.7– 11.7), 179 MC patients and 440 reference individuals were diagnosed with psoriasis (241.1 vs 131.8 events per 100,000 person-years), corresponding to one extra case of psoriasis in 91 patients with MC over 10 years. After adjustment for the matching variables (birth year, sex, county of residence, and calendar period) and level of education, we computed an adjusted hazard ratio (aHR) of 1.82 (95% CI = 1.53– 2.17). Stratified by sex, estimates were similar and when examining the aHR across different lengths of follow-up, we found significantly elevated estimates up to 10 years after MC diagnosis. Compared to MC-free siblings, the aHR was 1.85 (95% CI = 1.36– 2.51). Conclusion: Patients with MC are at an almost doubled risk of psoriasis compared to the general population. Clinicians need to consider psoriasis in MC patients with skin lesions. Keywords: microscopic colitis, psoriasis, epidemiology Microscopic colitis (MC) is a recently recognized inflammatory disease of the large intestine. 1 Typically, the disease affects patients aged 60 to 70 years and the disease is more common among women. 2 MC is characterized by symptoms such as non-bloody, watery diarrhea, abdominal pain, and weight loss. 3 Some patients may also report nocturnal diarrhea, urgency, and fecal incontinence. 4 The term microscopic colitis is a unifying concept for two main subtypes, primarily collagenous colitis (CC) and lymphocytic colitis (LC), subdivided by their histopathological presentation. The main diagnostic feature of CC is a thickened collagenous layer in the colonic mucosa, whereas LC is characterized by an increased number of intraepithelial lymphocytes. 5 Typically, there are no macroscopic aberrations in the colonic mucosa. In a 2019 cohort study examining the incidence of MC in Sweden, our group computed an overall incidence of MC in Sweden of 10.5 cases per 100000 person-years from 2006 to 2015 with higher rates in women (72% of patients). Psoriasis is a chronic immune-mediated disorder affecting primarily the skin. 6 However, some 10–30% 7–9 of patients also develop psoriatic arthritis with a typical onset approximately 10 years after the first signs of cutaneous lesions. Still, around 15% of patients will experience joint symptoms before the onset of skin manifestations. 10 Globally, the prevalence of psoriasis is estimated to be around 3% and in Sweden 2–4%). 11 There is a known link between psoriasis and other gastrointestinal (GI)-diseases such as celiac disease 12 and inflammatory bowel disease (IBD), 13 but data on the association between MC and psoriasis are scarce. A 2022 study from the USA 14 examining risk factors for MC (n = 1130) estimated a univariately derived odds ratio (OR) of -Abstract Truncated-
public, environmental & occupational health